Molecular-based therapies for renal cell carcinoma

Amnon Zisman, Allan J. Pantuck, Arie S. Belldegrun

Research output: Contribution to journalArticlepeer-review


The incidence of renal cell carcinoma (RCC) is rising steadily, but the ability to cure patients with metastatic RCC unfortunately remains limited. Emerging interest in gene therapy performance and safety is expressed by patients, medical institutes, and other agencies. It has become evident that better understanding of the genetic impairments and immune pathophysiology in RCC is essential for future improvement in patient care. Clinical trials now underway that are focusing on genetic and immune impairments will hopefully lead to future breakthroughs in RCC therapy. This paper reviews available gene therapies and other related therapeutic approaches for RCC and lists some of the current clinical trials focused on molecular-based therapies.

Original languageEnglish
Pages (from-to)55-61
Number of pages7
JournalCurrent Urology Reports
Issue number1
StatePublished - Feb 2001
Externally publishedYes


  • Human Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • Renal Cell Carcinoma
  • Renal Cell Carcinoma Cell Line
  • Renal Cell Carcinoma Patient


Dive into the research topics of 'Molecular-based therapies for renal cell carcinoma'. Together they form a unique fingerprint.

Cite this